Skip to main content

Table 2 Participants’ characteristics

From: Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile

 

Definition 1

(n = 318)

Definition 2

(n = 313*)

Definition 3

(n = 318)

Aβ-

Low burden

Aβ+

 

Aβ-

Low burden

Aβ+

 

Aβ-

Low burden

Aβ+

 

CSF- CL < 30

(n = 205, 64.5%)

CSF+ CL < 30

(n = 88, 27.7%)

CSF+ CL > 30

(n = 25, 7.86%)

P value

CSF- VR-

(n = 202, 64.5%)

CSF+ VR-

(n = 72, 23.0%)

CSF+ VR+

(n = 39, 12.5%)

P value

CL < 20

(n = 281, 88.4%)

20 - 40 CL

(n = 18, 5.66%)

CL > 40

(n = 19, 6.0%)

P value

Age, years

60.5 (4.32)

61.2 (5.14)

65.7 (2.64)1,2

<0.0001

60.5 (4.34)

60.8 (5.23)

64.9 (3.41)1,2

<0.0001

60.6 (4.61)

64.0 (3.53)3

65.5 (2.89)1

<0.0001

Female, n (%)

133 (64.9)

48 (54.5)

18 (72.0)

0.12

131 (64.9)

40 (55.6)

24 (61.5)

0.37

175 (62.3)

11 (61.1)

13 (68.4)

0.86

Education, years

13.4 (3.44)

13.7 (3.44)

12.2 (3.95)

0.19

13.6 (3.40)

13.5 (3.30)

12.5 (3.89)

0.20

13.5 (3.42)

13.3 (3.85)

12.5 (3.99)

0.53

MMSE

29.1 (0.98)

29.4 (0.91)

28.9 (1.09)

0.10

29.1 (0.95)

29.3 (0.90)

29.0 (1.09)

0.25

29.2 (0.95)

29.2 (1.04)

29.1 (1.03)

0.90

APOE-ε4 carriers, n (%)

85 (41.5)

70 (79.5)1

17 (68.0)

<0.0001

82 (40.6)

57 (79.2)1

28 (71.8)3

<0.0001

145 (51.6)

13 (72.2)

14 (73.7)

0.049

Centiloid (CL)

−4.58 (6.51)

7.06 (10.2)1

50.9 (12.6)1,2

<0.0001

−4.66 (6.51)

5.52 (9.40)1

36.3 (21.7)1,2

<0.0001

−2.17 (7.99)

28.2 (6.10)1

55.6 (10.6)1,2

<0.0001

CSF Aβ42/40

0.087 (0.009)

0.055 (0.010)1

0.040 (0.008)1,2

<0.0001

0.086 (0.009)

0.056 (0.011)1

0.045 (0.011)1,2

<0.0001

0.078 (0.016)

0.045 (0.010)1

0.041 (0.008)1

<0.0001

  1. Data are expressed as mean (M) and standard deviation (SD) or number of participants (n) and percentage (%), as appropriate. One-way ANOVA followed by Tukey corrected post hoc pairwise comparisons was used to compared age, education, and MMSE performance and Pearson’s chi-squared test to compare sex and APOE-ε4 status between groups within each definition. CSF Aβ42/40 and CL were compared with an ANCOVA adjusted by age and sex followed by Tukey corrected post hoc pairwise comparison. The P values indicated in the last column refer to the group main effect. Significant P values are marked in bold. “Low burden” refers to “Low burden of Ab pathology”. Abbreviations: Aβ amyloid-β, CL Centiloid, CSF cerebrospinal fluid, MMSE mini-mental state examination, VR visual read
  2. *In definition 2, we included 313 participants because 2 participants did not have Aβ PET visual read assessment available and 3 additional participants had a discrepant CSF and visual read assessment (negative CSF Aβ42/40 ratio but positive visual read). Participants with this biomarker profile do not fall in any of the definition 2 categories
  3. 1P < 0.0001 vs Aβ- group
  4. 2P < 0.0001 vs low burden group
  5. 3P < 0.01 vs Aβ- group
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193